XPeng Inc. · XPEV · FY2026 Q1 · Calendar Q2 2026

XPeng raises Q2 delivery outlook as physical AI strategy expands

The quarter supports a constructive growth case: delivery momentum, raised Q2 guidance, international expansion, and new AI-led businesses provide evidence of demand and growth. The case remains dependent on execution, stable margins, and regulatory progress.

Reported Before market openNYSEConsumer Cyclical $9.78B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $-0.27 Consensus $-0.11
EPS surprise -143.6% Reported versus consensus
Reported revenue $1.89B Consensus $1.87B
Revenue surprise +1.0% Reported versus consensus

Market reaction

prior-close to event-session close
Stock move -0.1% Event window
SPY move +0.6% Same window
Abnormal move -0.6% Stock minus SPY
Volume 1.6× Versus trailing sessions
Subsequent drift -26.5% Up to 20 sessions
XPEVSPY benchmark

Ask FN2 about XPEV FY2026 Q1

Transcript, numbers and history already loaded

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

Q2 delivery guidance was raised to 100,000–106,000 vehicles, while management emphasized a broader physical-AI strategy. International sales now exceed 20% of revenue, and R&D spending is focused on AI chips, autonomous driving, and robotics.

Guidance delta

Management raised Q2 delivery guidance to 100,000–106,000 vehicles and expects revenue to grow 50–60% sequentially.

Key takeaways

  • Q1 deliveries were 62,680 vehicles despite a weak Chinese NEV market.
  • Management raised Q2 delivery guidance and highlighted the GX SUV and Turing AI SoC rollout.
  • International sales exceed 20% of revenue, while robotics and robotaxi plans add longer-term optionality.

Management priorities

  • Scale the GX SUV and four new global models in H2 2026.
  • Expand international sales and localized production in Indonesia, Malaysia, and Austria.
  • Advance the Turing AI SoC, autonomous-driving systems, robotaxi platform, and humanoid robot.

Follow XPEV with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
XPEV EPS earnings history estimate and actual scatter chart 9 reported fiscal quarters and 4 future estimate-only quarters. Q4 '23 estimate $-3.27 Q4 '23 actual $-0.21, beat Q1 '24 estimate $-1.94 Q1 '24 actual $-0.20, beat Q2 '24 estimate $-1.26 Q2 '24 actual $-0.19, beat Q2 '25 estimate $-0.11 Q2 '25 actual $-0.07, beat Q3 '25 estimate $-0.01 Q3 '25 actual $-0.06, miss Q4 '25 estimate $0.00 Q4 '25 actual $0.06, beat Q1 '26 estimate $-0.11 Q1 '26 actual $-0.27, miss Q2 '26 estimate $-0.06 Q2 '26 actual $-0.21, miss Q3 '26 estimate $-0.74 Q4 '26 estimate $-0.12 Q1 '27 estimate $-0.34 Q2 '27 estimate $-0.28
Show 1 more >

Analyst Consensus ?

ConsensusHold17 ratings
Bullish1164.7%
Neutral317.7%
Bearish317.6%

Analyst 52W Price Targets

$10.29Previous close
$4.2Low
$22.23Average
$72High

Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Sep 24, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Barclays Underweight UnderweightMaintainAug 26, 2026
JP Morgan Overweight OverweightMaintainAug 25, 2026
Macquarie Outperform NeutralUpgradeMay 29, 2026
Freedom Capital Markets Buy HoldUpgradeJan 6, 2026
Freedom Broker Buy HoldUpgradeJan 6, 2026
Citigroup Buy BuyMaintainAug 20, 2025
B of A Securities Buy BuyMaintainAug 19, 2025
UBS Neutral SellUpgradeFeb 24, 2025
China Renaissance Buy HoldUpgradeNov 22, 2024
Bernstein Market Perform Market PerformMaintainNov 20, 2024
Morgan Stanley Overweight OverweightMaintainMar 11, 2024
CLSA Buy OutperformMaintainAug 8, 2023
HSBC Buy HoldUpgradeAug 7, 2023
Jefferies Buy HoldUpgradeJul 28, 2023
BOCOM International Sell NeutralDowngradeJul 7, 2023
Daiwa Capital Sell BuyDowngradeDec 14, 2022
Nomura Instinet Neutral BuyDowngradeJul 1, 2022
Show less

Named analyst price targets

Upside is calculated against the persisted previous close $10.29. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
UBSPaul Gong$12$10.93 +16.6%Sep 9, 2026
BarclaysJiong Shao$14$11.15 +36.1%Aug 25, 2026
BarclaysAnalyst unavailable$15$13.78 +45.8%Jul 16, 2026
JefferiesAlexious Lee$25.2$16.44 +144.9%May 29, 2026
MacquarieEugene Hsiao$19$16.44 +84.6%May 28, 2026
BarclaysAnalyst unavailable$17$17.84 +65.2%Feb 18, 2026
MacquarieEugene Hsiao$26$20.9 +152.7%Jan 15, 2026
Loop Capital MarketsRoman Lukianchikov$25$20.14 +143.0%Jan 6, 2026
Morgan StanleyTim Hsiao$34$26.04 +230.4%Nov 11, 2025
Goldman SachsTina Hou$24$18.57 +133.2%Jun 17, 2025
Morgan StanleyTim Hsaio$28$19.23 +172.1%Jun 12, 2025
BernsteinEunice Lee$19$20.5 +84.6%May 22, 2025
MacquarieEugene Hsiao$24$22.25 +133.2%May 21, 2025
BernsteinAnalyst unavailable$18$23.8 +74.9%Mar 19, 2025
CMB International SecuritiesJi Shi$16$12.64 +55.5%Nov 20, 2024
Morgan StanleyTim Hsiao$17$12.88 +65.2%Nov 6, 2024
CitigroupJeff Chung$14.6$12.72 +41.9%Sep 30, 2024
CitigroupJeff Chung$10.3$10.7 +0.1%Sep 24, 2024
MacquarieEugene Hsiao$10$8.41 -2.8%Sep 3, 2024
CitigroupJeff Chung$7.6$6.77 -26.1%Aug 21, 2024
BarclaysJiong Shao$7$6.77 -32.0%Aug 21, 2024
DaiwaKelvin Lau$11$8.1 +6.9%May 23, 2024
BernsteinEunice Lee$12$8.77 +16.6%May 22, 2024
BarclaysJiong Shao$8$8.77 -22.3%May 22, 2024
CFRAAaron Ho$8$7.76 -22.3%Apr 1, 2024
HSBCYuqian Ding$18.7$8.52 +81.7%Mar 22, 2024
Morgan StanleyTim Hsiao$18$9.89 +74.9%Mar 19, 2024
Morgan StanleyTim Hsiao$18.7$21.89 +81.7%Jul 28, 2023
J.P. MorganAnalyst unavailable$9$10.09 -12.5%Jan 11, 2023
DaiwaAnalyst unavailable$8$10.25 -22.3%Dec 14, 2022
HSBCAnalyst unavailable$15$10.47 +45.8%Dec 13, 2022
JefferiesAnalyst unavailable$4.2$7.07 -59.2%Nov 28, 2022
UBSAnalyst unavailable$13$7.76 +26.3%Nov 17, 2022
CitigroupAnalyst unavailable$27.87$18.73 +170.8%Aug 24, 2022
BarclaysJiong Shao$22$18.73 +113.8%Aug 23, 2022
NomuraMartin Heung$36.3$31.74 +252.8%Jul 1, 2022
CitigroupAnalyst unavailable$51.59$28.17 +401.4%Jun 21, 2022
J.P. MorganAnalyst unavailable$35$20.8 +240.1%May 24, 2022
BarclaysAnalyst unavailable$30$20.59 +191.5%May 24, 2022
US Tiger SecuritiesBo Pei$40$20.76 +288.7%May 24, 2022
UBSPaul Gong$34$25.87 +230.4%Apr 18, 2022
BernsteinEunice Lee$56$46.24 +444.2%Oct 28, 2021
Deutsche BankEdison Yu$51$40.28 +395.6%Aug 27, 2021
Credit SuisseBin Wang$72$43.39 +599.7%Aug 2, 2021
Show less

Track every rating change on XPEV the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Operating within the People's Republic of China, XPeng Inc. is an innovator in the electric vehicle (EV) sector, focusing on the creation and sale of intelligent, connected automobiles. It handles the entire process from conceptualization to market distribution. Its diverse lineup caters to various consumer needs, featuring SUV models like the G3 and G3i, the P7 performance-oriented sports sedan, and the P5, designed as a family-friendly sedan. Beyond manufacturing vehicles, XPeng supports its customers with a comprehensive ecosystem of services. These encompass sales and financial solutions (including contracts, leasing, and loan referrals), vehicle upkeep (maintenance and super charging), and a range of digital and convenience offerings such as insurance agency, ride-hailing, technical assistance, and music subscriptions. The company was established in 2015, with its headquarters located in Guangzhou, China.

Historical context

All XPEV earnings

Consumer Cyclical peers this season

Latest reports in the same sector

Latest beats and misses

Who reports next

Get the XPEV recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-06-12T09:22:40.805924+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-09-24T05:31:07.874311+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-24T05:31:07.870561+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-09-24. For educational purposes only; not investment advice.